NCT07179926View on ClinicalTrials.gov

Effects of Pasireotide Lar Therapy on Bone Metabolism

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Acromegaly Due to Pituitary AdenomaAcromegaly
Interventions
DIAGNOSTIC_TEST

morphometric spine radiography

Patients already on treatment with Pasireotide LAR or Pegvisomant will be evaluated using morphometric spine radiography and lumbar and femoral densitometry. Patients will undergo a 1-year follow-up.

Trial Locations (1)

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS UOC Endocrinologia e Diabetologia, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT07179926 - Effects of Pasireotide Lar Therapy on Bone Metabolism | Biotech Hunter | Biotech Hunter